RE:RE:Inflation Reduction Act (IRA) boosts biological drugs While traditional forms of manufacturing therapeutics, such as small molecules, biologics, peptides, and cell-based therapies, can be considered sufficient to meet the demands of patients with common diseases, certain cases require new ways to produce therapeutics quickly and at a large scale, such as occurred during the recent COVID-19 pandemic, new capabilities are being developed to meet the demands of scalability, flexibility, and reliability for the commercial and on-demand manufacturing and biomanufacturing of therapeutics for orphan/rare diseases like that happening fwith ONCY's pelareorep.